Perjeta 420mg Injection (Pertuzumab)

Perjeta 420mg Injection is a monoclonal antibody-based anticancer medicine. It is prescribed to treat certain types of HER2-positive breast cancer. It contains Pertuzumab as an active ingredient. It works by recognizing and attaching to the specific HER2 protein on the surface of cancer cells to inhibit the growth of cancer cells. Diagnostic testing is done to confirm the presence of HER2 before the treatment. Pertuzumab 420mg injection is commonly used in combination for advanced or early-stage breast cancers.

The injection is administered as an intravenous infusion by a qualified doctor in a hospital or clinical setting. The usual initial dose is 840mg for approximately 60 minutes, followed by 420mg every three weeks, infused over 30 to 60 minutes. A doctor determines the dosage of the Pertuzumab 420mg injection according to the type of cancer, treatment regimen, age, and overall health of the patient. It should not be self-administered. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include diarrhea, hair loss, nausea, fatigue, rash, decreased appetite, vomiting, constipation, weakness, and peripheral neuropathy. A few patients can undergo severe side effects, including heart problems, severe infusion-related reactions, and serious allergic reactions. Most of the Pertuzumab 420mg injection side effects tend to resolve when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

Check the heart function, especially the left ventricular ejection fraction, which should be assessed before and during treatment. The medicine can cause serious harm to an unborn baby, so pregnancy should be avoided during treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Pertuzumab 420mg injection must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

HER2-Positive Breast Cancer 

Like other anticancer medicines, Perjeta 420mg Injection (Pertuzumab 420mg) also has some common to severe side effects. These undesired symptoms are observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include the Following:
● Hair loss
● Feeling sick
● Rash
● Stomach inflammation
● Decreased blood cells (red cells, white cells, and platelets)
● Muscle pain
● Cough
● Heartburn
● Breathlessness
● Dizziness
● Fatigue
● Diarrhea
If you ever experience any unusual or serious side effects, contact your healthcare provider immediately.

The recommended dose of Perjeta 420mg Injection (Pertuzumab 420mg) may vary according to the stage of cancer, as well as age, weight, and other health factors of the patients. It should be given intravenously by a doctor or experienced nurse. The usual initial dose is 840mg for approximately 60 minutes, followed by 420mg every three weeks, infused over 30 to 60 minutes. Don't self-administer the injection, and don't double the dose to compensate for the missed dose.

● Harding, S., & Borley, A. (2025). Switching to a Fixed-dose Combined Pertuzumab and Trastuzumab With Recombinant Human Hyaluronidase Subcutaneous Injection to Treat Human Epidermal Growth Factor Receptor 2-positive Breast Cancer in Real-world UK Clinical Practice. Clinical Oncology, 37, 103671.
● Wang, Y. M. C., Ji, P., Hariharan, S., Wang, J., Okusanya, O., AbuAsal, B., ... & Zineh, I. (2024). Clinical pharmacology approaches to support approval of new routes of administration for therapeutic proteins. Clinical Pharmacology & Therapeutics, 115(3), 440-451.
● Ziegengeist, J. L., & Tan, A. R. (2025). A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer. Clinical Breast Cancer, 25(2), e124-e132.
● O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, D. L., Auvinen, P., Pulido, C., ... & Stamatovic, L. (2025). Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study. Clinical Breast Cancer.
● O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., ... & Wallmark, J. (2021). Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study. European Journal of Cancer, 152, 223-232.
● DuMond, B., Patel, V., Gross, A., Fung, A., & Weber, S. (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach. Journal of Oncology Pharmacy Practice, 27(5), 1214-1221.